Phototherapy for Alopecia Areata: Current Evidence and Clinical Considerations

Alopecia areata (AA) is driven by immune-mediated attack on the anagen hair follicle, with cytotoxic and helper T cells playing a central pathogenic role. While a wide range of immunomodulatory treatments have been explored over the decades, phototherapy remains one of the longest-standing physical modalities investigated for AA. Its rationale rests on the well-established ability of ultraviolet (UV) radiation to alter skin immune responses, induce apoptosis of activated T cells, and modify cytokine signaling within the skin. This article reviews the biological basis and clinical evidence for phototherapy in alopecia areata, with an emphasis on ultraviolet B (UVB)–based approaches.

Biological Rationale for Phototherapy in Alopecia Areata: Ultraviolet radiation is subdivided into UVA (320–400 nm), UVB (290–320 nm), and UVC (<290 nm). UVC light does not reach the earth’s surface and is not used therapeutically in medical clinics. UVA and UVB light differ substantially in skin penetration depth and biological effects. UVA penetrates more deeply into the dermis, whereas UVB is largely absorbed within the epidermis and superficial dermis, where many immune interactions relevant to AA occur.

UV radiation causes controlled DNA damage and oxidative stress in keratinocytes and resident immune cells. These effects lead to altered antigen presentation, reduced Langerhans cell density, suppression of delayed-type hypersensitivity reactions, and apoptosis of activated T lymphocytes. In AA, where perifollicular CD8+ T cells and interferon-driven signaling contribute to follicular immune privilege collapse, such immunosuppressive effects form the conceptual basis for phototherapy.

Importantly, therapeutic phototherapy aims to deliver carefully titrated doses of UV radiation to achieve immunomodulation while minimizing carcinogenic and photoaging risks. This distinction underlies the preference for medical phototherapy devices over natural sunlight exposure.

Overview of Phototherapy Modalities Relevant to AA: Historically, both UVA-based and UVB-based approaches have been explored in alopecia areata.

• UVA phototherapy, particularly in combination with psoralens (PUVA), has demonstrated efficacy in some patients with extensive AA, alopecia totalis, and alopecia universalis. Psoralens intercalate into DNA and, when activated by UVA, produce potent immunosuppressive effects. However, PUVA is associated with cumulative phototoxicity, increased long-term skin cancer risk, and logistical complexity, which has limited its modern use.
• UVB phototherapy does not require photosensitizing agents and has a more favorable safety profile. Although UVB penetrates less deeply than UVA, it effectively targets epidermal and superficial dermal immune cells, making it biologically plausible for AA treatment. Within UVB therapy, two principal forms exist: broadband UVB and narrowband UVB.

Broadband versus Narrowband UVB: Broadband UVB emits radiation across a wide wavelength range, approximately 290–350 nm. Earlier phototherapy units used this spectrum and showed benefit in inflammatory skin diseases such as psoriasis. However, wavelengths below 300 nm are largely erythemogenic and less therapeutically useful, while longer wavelengths carry less biological activity. As a result, broadband UVB exposes patients to non-optimal radiation components.

Narrowband UVB (NB-UVB) was developed to address this limitation. It emits a much narrower spectrum centered around 311–313 nm, which is considered the most therapeutically effective UVB range. NB-UVB has largely replaced broadband UVB for many dermatologic indications due to improved efficacy and reduced cumulative dose requirements.

From an immunological perspective, NB-UVB has been shown to efficiently deplete cutaneous T cells, alter cytokine expression, and promote immune tolerance within the skin. These properties prompted investigators to explore its role in AA, particularly as a potentially safer alternative to PUVA.

Clinical Evidence for UVB Phototherapy in Alopecia Areata: Early clinical observations in the 1960s, using localized UV sources such as the Kromayer ultraviolet lamp, suggested that targeted UV exposure could induce hair regrowth in patchy AA. In these studies, biologically active UV wavelengths were applied directly to alopecic patches until mild erythema developed. A substantial proportion of patients experienced partial or complete regrowth within several months, particularly those who had limited hair loss.

Subsequent investigations extended these observations to NB-UVB. Small case series and uncontrolled studies evaluated patients with extensive AA who received whole-body or localized NB-UVB therapy two to three times per week over several months. While results were variable, a consistent pattern emerged: patients with patchy AA were more likely to respond than those with alopecia totalis or universalis, and regrowth was often incomplete or transient.

More recent analyses suggest that NB-UVB alone is generally less effective in AA than in classic inflammatory dermatoses such as psoriasis or vitiligo. Hair follicles reside deeper than the epidermis, and the limited penetration depth of UVB light may restrict its ability to fully suppress perifollicular immune activity in severe disease. Nevertheless, documented cases of cosmetically meaningful regrowth indicate that UVB phototherapy can exert clinically relevant effects in selected patients.

Treatment Technique and Practical Considerations: UVB phototherapy for AA may be administered using full-body cabinets or targeted devices designed for scalp exposure. For scalp involvement, hair density and pigmentation can impede UV penetration; therefore, techniques such as hair parting, clipping, or the use of fiber-optic or comb-based UV devices may be employed to improve delivery to the skin surface.

Treatment protocols typically begin with low doses based on the patient’s minimal erythema dose, followed by gradual dose escalation. Sessions are commonly scheduled two to three times weekly, with visible responses, if they occur, emerging after 8–12 weeks. Emollients are often applied prior to treatment to enhance light penetration and reduce surface reflection.

Importantly, phototherapy is generally discontinued if no regrowth is observed after a reasonable treatment window, as prolonged exposure without response only increases cumulative UV burden.

Durability of Response and Relapse: One of the central limitations of phototherapy in AA is the durability of response. Even among responders, relapse after treatment discontinuation is common. This observation highlights the fact that phototherapy modulates local immune activity rather than permanently correcting the underlying autoimmune predisposition.

In historical series, patients who achieved full or near-full regrowth frequently experienced renewed hair loss several months after stopping therapy. This pattern remains evident in more recent NB-UVB studies and contrasts with diseases such as vitiligo, where repigmentation induced by phototherapy can be much more stable.

Safety Profile and Long-Term Risks: UVB phototherapy is generally well tolerated when administered under medical supervision. Transient erythema is expected and often used as a dosing guide. Pruritus, dryness, and tanning are common but typically mild. Blistering burns are rare when protocols are followed appropriately.

Pigmentary changes, including lentigines or hypopigmented macules, may appear after repeated treatments. While UVB is considered less carcinogenic than UVA, cumulative exposure to UV radiation is associated with photoaging and increased skin cancer risk over time. Although NB-UVB has not been conclusively linked to increased melanoma risk, long-term surveillance data remain limited, particularly in younger patients.

For these reasons, careful patient selection, documentation of cumulative dose, and regular skin examinations are essential components of responsible phototherapy practice.

Current Position of Phototherapy in AA Management: In the modern therapeutic landscape, phototherapy occupies a niche role in treating alopecia areata. Advances in understanding AA pathogenesis and the emergence of highly targeted immunomodulatory agents, particularly JAK inhibitor drugs, have shifted treatment paradigms. Compared with these newer approaches, UVB phototherapy offers modest efficacy, unpredictable durability, and logistical demands that limit widespread adoption.

Nevertheless, phototherapy retains relevance in specific contexts. It may be considered for patients with patchy AA who prefer non-systemic treatments, for individuals with contraindications to pharmacologic immunosuppression, or in settings where access to newer therapies is limited. Phototherapy for alopecia areata is still available in some clinics in the Middle East, North Africa and some countries in East Asia. Its long history in dermatology, relatively low systemic risk, and well-characterized safety profile support its continued inclusion as a treatment option – albeit not a first-line solution.

Conclusion: Phototherapy, particularly UVB-based modalities, represents one of the earliest immunomodulatory strategies explored for alopecia areata. By inducing local immune suppression and T-cell apoptosis, UVB can promote hair regrowth in a subset of patients, especially those with limited disease. However, responses are variable, relapse is common, and efficacy diminishes in more extensive forms of AA.

Contemporary evidence suggests that while UVB phototherapy is biologically plausible and clinically active, its role is best defined as adjunctive or selective rather than central. Research into optimized delivery methods, combination approaches, and patient stratification may further clarify where phototherapy can provide meaningful benefit in this complex autoimmune hair disorder.

Bibliography